Table 1.
Patient characteristics
| Characteristics | Chemoradiotherapy plus toripalimab (n = 22) |
|---|---|
| Age, median (IQR), years | 54.5 (40.5–57.5) |
| Gender | |
| Male | 15 (68.2) |
| Female | 7 (31.8) |
| Karnofsky performance status score | |
| 90 | 22 (100.0) |
| Smoking status | |
| Smokers | 4 (18.2) |
| Nonsmokers | 18 (81.8) |
| Histologic findings | |
| Nonkeratinizing undifferentiated | 22 (100.0) |
| T stage | |
| T2 | 1 (4.5) |
| T3-4 | 21 (95.5) |
| N stage | |
| N1 | 4 (18.2) |
| N2-3 | 18 (81.8) |
| Bone metastases | |
| No | 13 (59.1) |
| Yes | 9 (40.9) |
| Liver metastases | |
| No | 15 (68.2) |
| Yes | 7 (31.8) |
| Lung metastases | |
| No | 15 (68.2) |
| Yes | 7 (31.8) |
| Distant LN metastases | |
| No | 19 (86.4) |
| Yes | 3 (13.6) |
| Metastatic lesions | |
| 1–2 | 9 (40.9) |
| 3–5 | 7 (31.8) |
| >5 | 6 (27.3) |
| EBV DNA, median (IQR), cp/ml | 7,225 (885–44,150) |